만성염증탈수초다발신경병증(CIDP) : 신규 요법, 미충족 수요 및 TPP 인사이트 리포트(2026년)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Emerging Therapy and TPP Insights

Thelansis's "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Overview

Chronic Inflammatory Demyelinating Polyneuropathy is an immune-mediated peripheral neuropathy driven by T-cell and autoantibody-mediated myelin destruction, causing progressive or relapsing proximal and distal limb weakness with sensory impairment. Patients present with symmetric weakness, areflexia, gait instability, and sensory disturbance evolving over months. Diagnosis combines nerve conduction studies showing demyelination, CSF cytoalbuminous dissociation, and nerve biopsy when indicated; disability scales reflect severity. Corticosteroids, intravenous immunoglobulin, and plasma exchange are established first-line treatments; subcutaneous immunoglobulin offers convenient maintenance. Subcutaneous efgartigimod is an approved FcRn-targeted option reducing pathogenic IgG and relapse risk. Regular neurological assessments guide therapy escalation. Early treatment and multidisciplinary rehabilitation support sustained remission.

Key Highlights

• In France, the prevalent CIDP population is projected to increase from approximately 3,808 in 2025 to 3,992 by 2035.
• CIDP is a rare autoimmune neurological disorder characterized by progressive weakness and sensory dysfunction.
• Early diagnosis and treatment remain critical to preventing irreversible nerve damage and disability.
• Immunoglobulin therapy continues to represent the cornerstone of disease management.
• Emerging targeted immunotherapies are expanding treatment options for refractory disease.

Market Overview

• The Italy CIDP market is projected to grow from approximately $145 MN to $375 MN by 2035.
• Market growth is supported by:
• Increasing utilization of IVIG, SCIG, and targeted immunotherapies
• Improved diagnosis and long-term disease management
• Market value growth is driven by chronic treatment requirements and increasing adoption of advanced therapies.
• Future growth will depend on novel immune-modulating therapies and improved long-term disease control strategies.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Takeda
• Kine Sciences Co., Ltd.
• Immunovant Sciences GmbH
• Argenx
• Grifols Therapeutics LLC
• Nuvig Therapeutics, Inc.
• Sanofi
• Kite, A Gilead Company
• Janssen Research & Development, LLC
• Kedrion S.p.A.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)